Proprietary AI analyst is now available

Cosmo Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cosmo Pharmaceuticals and similar public comparables like Enliven Therapeutics, Avadel Pharmaceuticals, Immunome, Pfizer India and more.

Cosmo Pharmaceuticals Overview

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.


Founded

1997

HQ

Switzerland

Employees

322

Financials (LTM)

Revenue: $122M
EBITDA: $13M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cosmo Pharmaceuticals Financials

Cosmo Pharmaceuticals reported last 12-month revenue of $122M and EBITDA of $13M.

In the same LTM period, Cosmo Pharmaceuticals generated $60M in gross profit, $13M in EBITDA, and had net loss of ($2M).

Revenue (LTM)


Cosmo Pharmaceuticals P&L

In the most recent fiscal year, Cosmo Pharmaceuticals reported revenue of - and net income of -.

See analyst estimates for Cosmo Pharmaceuticals
LTM2025202620272028
Revenue$122M$121M
Gross Profit$60M$58M
Gross Margin49%48%
EBITDA$13M$11M
EBITDA Margin11%9%
EBIT Margin(2%)(3%)
Net Profit($2M)($4M)
Net Margin(1%)(3%)

Financial data powered by Morningstar, Inc.

Cosmo Pharmaceuticals Stock Performance

Cosmo Pharmaceuticals has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


Cosmo Pharmaceuticals' stock price is $123.51.

Cosmo Pharmaceuticals share price increased by 70.3% in the last year.

See more trading valuation data for Cosmo Pharmaceuticals
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B0.0%-16.4%70.3%-

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cosmo Pharmaceuticals Valuation Multiples

Cosmo Pharmaceuticals trades at 16.2x EV/Revenue multiple, and 153.9x EV/EBITDA.

See NTM and 2027E valuation multiples for Cosmo Pharmaceuticals

EV / Revenue (LTM)


Cosmo Pharmaceuticals Financial Valuation Multiples

As of June 7, 2026, Cosmo Pharmaceuticals has market cap of $2B and EV of $2B.

Cosmo Pharmaceuticals has a P/E ratio of (1351.9x).

LTM2025202620272028
EV/Revenue16.2x16.4x
EV/EBITDA153.9x179.0x
EV/EBITn/mn/m
EV/Gross Profit33.1x33.8x
P/En/mn/m
EV/FCFn/mn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cosmo Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cosmo Pharmaceuticals Margins & Growth Rates

See estimated margins and future growth rates for Cosmo Pharmaceuticals

Cosmo Pharmaceuticals Margins

20252026202720282029
Gross Margin48%50%
EBITDA Margin9%12%
EBIT Margin(3%)(0%)
Net Margin(3%)1%
FCF Margin4%10%

Cosmo Pharmaceuticals Growth Rates

25/2626/2727/2828/29
Revenue Growth2%
Gross Profit Growth5%
EBITDA Growth38%
EBIT Growth(86%)
Net Profit Growth(142%)
FCF Growth156%

Data powered by FactSet, Inc. and Morningstar, Inc.

Cosmo Pharmaceuticals Operational KPIs

Cosmo Pharmaceuticals' Rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cosmo Pharmaceuticals' Rule of X is 17% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Cosmo Pharmaceuticals
LTMLast FY2025202620272028
Rule of 4028%14%-
Bessemer Rule of X54%17%-
G&A Expenses to Revenue27%-26%
R&D Expenses to Revenue32%-33%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cosmo Pharmaceuticals Competitors

Cosmo Pharmaceuticals competitors include Enliven Therapeutics, Avadel Pharmaceuticals, Immunome, Pfizer India, BioCryst Pharma, Mineralys Therapeutics, OneSource Specialty, Bavarian Nordic, Duality Biotherapeutics and Ultragenyx.

Most Cosmo Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Enliven Therapeutics--(13.9x)(13.5x)
Avadel Pharmaceuticals-0.4x-0.7x
Immunome219.7x303.7x(6.9x)(6.4x)
Pfizer India6.9x6.8x16.6x18.9x
BioCryst Pharma3.1x3.5x7.8x-
Mineralys Therapeutics--(9.0x)(8.3x)
OneSource Specialty15.4x13.9x70.8x55.7x
Bavarian Nordic1.9x2.0x4.6x5.6x

This data is available for Pro users. Sign up to see all Cosmo Pharmaceuticals competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cosmo Pharmaceuticals

When was Cosmo Pharmaceuticals founded?Cosmo Pharmaceuticals was founded in 1997.
Where is Cosmo Pharmaceuticals headquartered?Cosmo Pharmaceuticals is headquartered in Switzerland.
How many employees does Cosmo Pharmaceuticals have?As of today, Cosmo Pharmaceuticals has over 322 employees.
Who is the CEO of Cosmo Pharmaceuticals?Cosmo Pharmaceuticals' CEO is Giovanni Di Napoli.
Is Cosmo Pharmaceuticals publicly listed?Yes, Cosmo Pharmaceuticals is a public company listed on Berlin Stock Exchange.
What is the stock symbol of Cosmo Pharmaceuticals?Cosmo Pharmaceuticals trades under C43 ticker.
When did Cosmo Pharmaceuticals go public?Cosmo Pharmaceuticals went public in 2007.
Who are competitors of Cosmo Pharmaceuticals?Cosmo Pharmaceuticals main competitors include Enliven Therapeutics, Avadel Pharmaceuticals, Immunome, Pfizer India, BioCryst Pharma, Mineralys Therapeutics, OneSource Specialty, Bavarian Nordic, Duality Biotherapeutics, Ultragenyx.
What is the current market cap of Cosmo Pharmaceuticals?Cosmo Pharmaceuticals' current market cap is $2B.
What is the current revenue of Cosmo Pharmaceuticals?Cosmo Pharmaceuticals' last 12 months revenue is $122M.
What is the current revenue growth of Cosmo Pharmaceuticals?Cosmo Pharmaceuticals revenue growth (NTM/LTM) is 17%.
What is the current EV/Revenue multiple of Cosmo Pharmaceuticals?Current revenue multiple of Cosmo Pharmaceuticals is 16.2x.
What is the current EBITDA of Cosmo Pharmaceuticals?Cosmo Pharmaceuticals' last 12 months EBITDA is $13M.
What is Cosmo Pharmaceuticals' EBITDA margin?Cosmo Pharmaceuticals' last 12 months EBITDA margin is 11%.
What is the current EV/EBITDA multiple of Cosmo Pharmaceuticals?Current EBITDA multiple of Cosmo Pharmaceuticals is 153.9x.
What is the current FCF of Cosmo Pharmaceuticals?Cosmo Pharmaceuticals' last 12 months FCF is $8M.
What is Cosmo Pharmaceuticals' FCF margin?Cosmo Pharmaceuticals' last 12 months FCF margin is 6%.
What is the current EV/FCF multiple of Cosmo Pharmaceuticals?Current FCF multiple of Cosmo Pharmaceuticals is 252.9x.
How many companies Cosmo Pharmaceuticals has acquired to date?Cosmo Pharmaceuticals hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Cosmo Pharmaceuticals has invested to date?Cosmo Pharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Cosmo Pharmaceuticals

Lists including Cosmo Pharmaceuticals

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial